Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia

The purpose of this study is to determine the Optimal dose for safety and efficacy in the treatment of cervical dystonia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cervical Dystonia Dyskinesias Dystonia Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Torticollis

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Brisbane, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female aged 18~75
Have no clinically significant medical condition
Cervical dystonia

Exclusion criteria

Pregnant or lactation
Subjects who have been administered the following drugs within the previous 1 month

Treatment and study plan

MT10109

Biological

Botulinum toxin type A

BOTOX(Registered trade mark)

Biological

Botulinum toxin type A

Primary outcomes

Number of adverse events

Time frame: Day 30

Sponsors and collaborators

Lead sponsor

Medy-Tox

Industry

Registry information

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: May 1, 2012
Registry last updated: Sep 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed